Bio Rad Laboratories (BIO) Saham Harga

Bio Rad Laboratories Harga

NYSE·DITUTUP
356,26USD-4,93 (-1,37 %)
Pasar ditutup

Revenue has compounded at 3,8% per year over the past 19 years to 2,58 miliar USD. Earnings per share have grown at 11,1% per year over the last 19 years. Bio Rad Laboratories's net margin stands at 29,4%, down from 145,6% several years earlier. Analysts set a median price target of 372,30 USD, implying 4,5% above the current price. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus. Over the past year Bio Rad Laboratories shares have gained 23,5%. The stock trades about 47% above its 52-week low.

Harga saham Bio Rad Laboratories

Volume
Detail

Kurs

ⓘ

Tinjauan

Diagram kurs saham memberikan wawasan terperinci dan dinamis tentang kinerja saham Bio Rad Laboratories dan menampilkan harga yang teragregasi harian, mingguan atau bulanan. Pengguna dapat beralih antar kerangka waktu yang berbeda untuk menganalisis sejarah saham secara hati-hati dan mengambil keputusan investasi yang berbasis data.

Fungsi Intraday

Fungsi Intraday menyediakan data waktu nyata dan memungkinkan investor untuk melihat fluktuasi harga saham Bio Rad Laboratories selama hari perdagangan, agar dapat mengambil keputusan investasi yang tepat waktu dan strategis.

Total Return dan Perubahan Harga Relatif

Lihat total return dari saham Bio Rad Laboratories untuk menilai profitabilitasnya seiring waktu. Perubahan harga relatif, berdasarkan harga tersedia pertama dalam kerangka waktu yang dipilih, memberikan wawasan dalam kinerja saham dan membantu dalam mengevaluasi potensi investasinya.

Interpretasi dan Investasi

Gunakan data komprehensif yang disajikan dalam diagram kurs saham untuk menganalisis tren pasar, pergerakan harga, dan potensi return dari Bio Rad Laboratories. Ambil keputusan investasi yang berinformasi dengan membandingkan berbagai kerangka waktu dan mengevaluasi data intraday untuk manajemen portofolio yang dioptimalkan.

Bio Rad Laboratories Sejarah Kurs
TanggalBio Rad Laboratories Harga
14/8/2026356,26 USD
13/8/2026361,19 USD
12/8/2026362,08 USD
11/8/2026356,25 USD
10/8/2026351,34 USD
7/8/2026352,47 USD
6/8/2026342,43 USD
5/8/2026345,41 USD
4/8/2026334,39 USD
3/8/2026334,71 USD
31/7/2026325,48 USD
30/7/2026326,72 USD
29/7/2026329,40 USD
27/7/2026319,42 USD
23/7/2026316,38 USD
22/7/2026305,96 USD
21/7/2026301,70 USD
20/7/2026301,90 USD
17/7/2026304,36 USD
16/7/2026300,98 USD
15/7/2026295,73 USD
14/7/2026298,34 USD
13/7/2026298,26 USD
10/7/2026296,11 USD
9/7/2026297,28 USD
8/7/2026290,00 USD
7/7/2026292,50 USD
6/7/2026293,29 USD
2/7/2026296,86 USD
1/7/2026297,09 USD
30/6/2026293,61 USD
29/6/2026295,99 USD
26/6/2026300,79 USD
25/6/2026298,29 USD
24/6/2026280,05 USD
23/6/2026270,32 USD
22/6/2026277,88 USD
18/6/2026282,86 USD
17/6/2026289,82 USD
16/6/2026292,19 USD
15/6/2026287,62 USD
12/6/2026287,31 USD
11/6/2026290,30 USD
10/6/2026292,96 USD
9/6/2026297,17 USD
8/6/2026291,31 USD
5/6/2026297,88 USD
4/6/2026310,63 USD
3/6/2026303,79 USD
2/6/2026306,69 USD
1/6/2026309,83 USD
29/5/2026317,68 USD
28/5/2026317,98 USD
27/5/2026303,68 USD
26/5/2026290,13 USD
22/5/2026287,03 USD
21/5/2026288,46 USD
20/5/2026281,30 USD
19/5/2026281,05 USD
18/5/2026281,82 USD
15/5/2026247,53 USD
14/5/2026246,27 USD
13/5/2026243,51 USD
12/5/2026241,71 USD
11/5/2026243,79 USD
8/5/2026254,32 USD
7/5/2026257,32 USD
6/5/2026259,02 USD
5/5/2026257,12 USD
4/5/2026257,86 USD
1/5/2026256,55 USD
30/4/2026280,12 USD
29/4/2026275,15 USD
28/4/2026279,34 USD
27/4/2026287,29 USD
24/4/2026287,84 USD
23/4/2026281,42 USD
22/4/2026300,78 USD
21/4/2026305,67 USD
20/4/2026303,34 USD
17/4/2026299,02 USD
16/4/2026291,09 USD
15/4/2026295,96 USD
14/4/2026292,23 USD
13/4/2026288,17 USD
10/4/2026279,25 USD
9/4/2026277,50 USD
8/4/2026281,15 USD
7/4/2026278,00 USD
6/4/2026278,85 USD
2/4/2026279,99 USD
1/4/2026278,36 USD
31/3/2026278,75 USD
30/3/2026270,36 USD
27/3/2026265,40 USD
26/3/2026276,53 USD
25/3/2026273,60 USD
24/3/2026272,12 USD
23/3/2026265,00 USD
20/3/2026264,49 USD
19/3/2026265,00 USD
18/3/2026265,00 USD
17/3/2026269,48 USD
16/3/2026261,24 USD
13/3/2026262,80 USD
12/3/2026261,82 USD
11/3/2026269,89 USD
10/3/2026267,85 USD
9/3/2026271,44 USD
6/3/2026269,85 USD
5/3/2026279,03 USD
4/3/2026284,68 USD
3/3/2026280,19 USD
2/3/2026279,59 USD
27/2/2026278,44 USD
26/2/2026275,21 USD
25/2/2026269,65 USD
24/2/2026268,70 USD
23/2/2026268,25 USD
20/2/2026271,30 USD
19/2/2026271,90 USD
18/2/2026270,67 USD
17/2/2026264,93 USD
13/2/2026256,56 USD
12/2/2026256,56 USD
11/2/2026292,42 USD
10/2/2026293,69 USD
9/2/2026299,96 USD
8/2/2026294,90 USD
6/2/2026301,50 USD
5/2/2026301,50 USD
4/2/2026299,54 USD
3/2/2026305,90 USD
2/2/2026298,98 USD
1/2/2026297,43 USD
30/1/2026293,70 USD
29/1/2026293,70 USD
28/1/2026294,91 USD
27/1/2026299,79 USD
26/1/2026297,71 USD
25/1/2026299,28 USD
23/1/2026296,57 USD
22/1/2026296,57 USD
21/1/2026305,22 USD
20/1/2026311,54 USD
19/1/2026312,76 USD
16/1/2026313,53 USD
15/1/2026313,53 USD
14/1/2026322,06 USD
13/1/2026318,25 USD
12/1/2026322,17 USD
11/1/2026323,00 USD
9/1/2026323,82 USD
8/1/2026323,82 USD
7/1/2026319,08 USD
6/1/2026324,09 USD
5/1/2026325,50 USD
4/1/2026322,34 USD
2/1/2026305,27 USD
1/1/2026305,27 USD
31/12/2025302,99 USD
30/12/2025302,99 USD
29/12/2025304,51 USD
28/12/2025303,73 USD
26/12/2025303,88 USD
25/12/2025303,88 USD
24/12/2025301,75 USD
23/12/2025301,75 USD
22/12/2025301,03 USD
21/12/2025304,85 USD
19/12/2025301,53 USD
18/12/2025301,53 USD
17/12/2025299,86 USD
16/12/2025301,28 USD
15/12/2025302,02 USD
14/12/2025307,92 USD
12/12/2025308,13 USD
11/12/2025308,13 USD
10/12/2025313,97 USD
9/12/2025315,00 USD
8/12/2025308,05 USD
7/12/2025308,53 USD
5/12/2025317,69 USD
4/12/2025317,69 USD
3/12/2025320,06 USD
2/12/2025320,34 USD
1/12/2025318,56 USD
30/11/2025321,50 USD
28/11/2025324,86 USD
27/11/2025324,86 USD
26/11/2025327,03 USD
25/11/2025327,03 USD
24/11/2025332,21 USD
23/11/2025322,48 USD
21/11/2025316,70 USD
20/11/2025316,70 USD
19/11/2025303,61 USD
18/11/2025304,79 USD
17/11/2025307,78 USD
16/11/2025304,06 USD
14/11/2025313,15 USD
13/11/2025313,15 USD
12/11/2025316,89 USD
11/11/2025327,28 USD
10/11/2025313,33 USD
9/11/2025307,38 USD
7/11/2025305,56 USD
6/11/2025305,56 USD
5/11/2025306,55 USD
4/11/2025310,01 USD
3/11/2025310,96 USD
2/11/2025311,43 USD
31/10/2025319,55 USD
30/10/2025319,55 USD
29/10/2025304,61 USD
28/10/2025319,47 USD
27/10/2025330,42 USD
26/10/2025336,12 USD
24/10/2025339,75 USD
23/10/2025339,75 USD
22/10/2025338,67 USD
21/10/2025333,97 USD
20/10/2025331,27 USD
19/10/2025321,90 USD
17/10/2025313,02 USD
16/10/2025310,02 USD
15/10/2025312,39 USD
14/10/2025305,85 USD
13/10/2025305,05 USD
12/10/2025303,71 USD
10/10/2025297,72 USD
9/10/2025297,72 USD
8/10/2025300,63 USD
7/10/2025302,83 USD
6/10/2025296,52 USD
5/10/2025309,17 USD
3/10/2025305,54 USD
2/10/2025305,49 USD
1/10/2025294,24 USD
30/9/2025297,95 USD
29/9/2025280,39 USD
28/9/2025270,11 USD
25/9/2025271,36 USD
24/9/2025270,41 USD
23/9/2025276,62 USD
22/9/2025282,07 USD
21/9/2025283,36 USD
19/9/2025284,09 USD
18/9/2025284,07 USD
17/9/2025286,49 USD
16/9/2025280,29 USD
15/9/2025282,26 USD
14/9/2025280,21 USD
12/9/2025280,36 USD
11/9/2025280,34 USD
10/9/2025285,90 USD
9/9/2025276,91 USD
8/9/2025285,95 USD
7/9/2025290,38 USD
5/9/2025295,45 USD
4/9/2025295,43 USD
3/9/2025289,43 USD
2/9/2025288,05 USD
1/9/2025290,71 USD
29/8/2025297,90 USD
28/8/2025297,88 USD
27/8/2025293,67 USD
26/8/2025292,84 USD
25/8/2025296,60 USD
24/8/2025297,37 USD
22/8/2025307,69 USD
21/8/2025303,82 USD
20/8/2025285,03 USD
19/8/2025288,16 USD
18/8/2025288,37 USD
Access this data via the Eulerpool API
Get Free API Key

Pendapatan Bio Rad Laboratories, EBIT, Laba Bersih

  • 3 tahun

  • 5 tahun

  • 10 tahun

  • 25 Tahun

  • Maks

Pendapatan
EBIT
Laba Bersih
Details
Date
Pendapatan
EBIT
Laba Bersih
1 Jan 2023
2,67 miliar USD
337,80 Juta. USD
-637,32 Juta. USD
1 Jan 2024
2,57 miliar USD
269,00 Juta. USD
-1,84 miliar USD
1 Jan 2025
2,58 miliar USD
270,50 Juta. USD
759,90 Juta. USD
1 Jan 2026 (e)
2,57 miliar USD
-406,54 Juta. USD
267,56 Juta. USD
1 Jan 2027 (e)
2,63 miliar USD
-419,88 Juta. USD
282,93 Juta. USD
1 Jan 2028 (e)
2,76 miliar USD
-435,36 Juta. USD
314,50 Juta. USD
1 Jan 2029 (e)
2,81 miliar USD
-442,98 Juta. USD
343,36 Juta. USD
1 Jan 2030 (e)
2,89 miliar USD
-455,45 Juta. USD
388,22 Juta. USD

Bio Rad Laboratories Saham Kennzahlen

Terakhir diperbarui 18 Agu 2026, 23.54
 
OMSETmiliar USD
PERTUMBUHAN PENDAPATAN%
MARGIN KOTOR%
PENDAPATAN KOTORmiliar USD
EBITJuta. USD
MARGIN EBIT%
LABA BERSIHmiliar USD
PERTUMBUHAN LABA BERSIH%
JUMLAH SAHAMJuta.
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
2,022,072,162,292,312,552,922,802,672,572,582,572,632,762,812,89
-7,172,434,456,020,9210,1314,81-4,11-4,68-3,930,66-0,392,334,751,782,81
55,5255,0354,9553,4554,3956,4656,0655,9253,3953,7051,9951,9951,9951,9951,9951,99
1,121,141,191,221,261,441,641,571,431,381,341,341,371,431,461,50
166,0053,00115,00-108,00229,00443,00501,00482,00337,00269,00270,00-406,00-419,00-435,00-442,00-455,00
8,222,565,32-4,729,9117,4117,1517,2012,6210,4810,45-15,78-15,91-15,77-15,75-15,77
0,110,030,110,361,763,814,25-3,63-0,64-1,840,760,270,280,310,340,39
28,41-75,22307,14215,79388,33116,9511,54-185,26-82,44189,48-141,16-64,825,6211,359,2413,12
29,4729,5530,1129,8830,2230,1729,9229,7928,8228,0027,0127,0127,0127,0127,0127,01
Detail

GuV

ⓘ

Pendapatan dan Pertumbuhan

Pendapatan Bio Rad Laboratories dan pertumbuhan pendapatan merupakan hal penting untuk pemahaman kesehatan finansial dan efisiensi operasional sebuah perusahaan. Peningkatan pendapatan yang konstan menunjukkan kemampuan perusahaan untuk memasarkan dan menjual produk atau jasanya secara efektif, sementara persentase pertumbuhan pendapatan memberikan gambaran tentang kecepatan pertumbuhan perusahaan dari tahun ke tahun.

Margin Bruto

Margin bruto adalah faktor penting yang menunjukkan persentase pendapatan yang melebihi biaya produksi. Margin bruto yang lebih tinggi menunjukkan efisiensi sebuah perusahaan dalam mengendalikan biaya produksinya serta menjanjikan potensi rentabilitas dan stabilitas finansial.

EBIT dan Margin EBIT

EBIT (Earnings Before Interest and Taxes) dan margin EBIT memberikan wawasan mendalam tentang rentabilitas sebuah perusahaan, tanpa memperhitungkan dampak dari bunga dan pajak. Investor sering menilai metrik ini untuk mengevaluasi efisiensi operasional dan rentabilitas yang inheren dari perusahaan, terlepas dari struktur keuangannya dan lingkungan perpajakannya.

Pendapatan dan Pertumbuhan

Pendapatan bersih dan pertumbuhan yang diikuti sangat penting bagi investor yang ingin memahami rentabilitas sebuah perusahaan. Pertumbuhan pendapatan yang konstan menegaskan kemampuan perusahaan untuk meningkatkan rentabilitasnya dari waktu ke waktu dan mencerminkan efisiensi operasional, daya saing strategis, dan kesehatan finansial.

Saham yang Beredar

Saham yang beredar merujuk pada jumlah total saham yang dikeluarkan oleh perusahaan. Ini penting untuk menghitung metrik utama seperti laba per saham (EPS), yang sangat penting bagi investor untuk mengevaluasi rentabilitas perusahaan berdasarkan per saham dan menyediakan gambaran yang lebih terinci tentang kesehatan finansial dan penilaian.

Interpretasi Perbandingan Tahunan

Membandingkan data tahunan memungkinkan investor untuk mengidentifikasi tren, mengevaluasi pertumbuhan perusahaan, dan memprediksi kinerja potensial di masa depan. Menganalisis bagaimana metrik seperti pendapatan, pendapatan, dan margin berubah dari tahun ke tahun dapat memberikan wawasan berharga tentang efisiensi operasional, daya saing, dan kesehatan finansial perusahaan.

Ekspektasi dan Prakiraan

Investor sering membandingkan data finansial saat ini dan masa lalu dengan ekspektasi pasar. Perbandingan ini membantu dalam menilai apakah kinerja Bio Rad Laboratories sesuai ekspektasi, di bawah rata-rata atau di atas rata-rata dan menyediakan data krusial untuk keputusan investasi.

Margin saham Bio Rad Laboratories

Analisis margin Bio Rad Laboratories menampilkan margin kotor, margin EBIT, serta margin laba dari Bio Rad Laboratories. Margin EBIT (EBIT/penjualan) menunjukkan persentase penjualan yang tersisa sebagai laba operasional. Margin laba menunjukkan persentase penjualan yang tersisa untuk Bio Rad Laboratories.

  • 3 tahun

  • 5 tahun

  • 10 tahun

  • 25 Tahun

  • Maks

Margin kotor
Margin EBIT
Margin laba
Details
Date
Margin kotor
Margin EBIT
Margin laba
1 Jan 2021
56,05 %
17,17 %
145,57 %
1 Jan 2022
55,93 %
17,22 %
-129,45 %
1 Jan 2023
53,42 %
12,65 %
-23,86 %
1 Jan 2024
53,73 %
10,48 %
-71,86 %
1 Jan 2025
52,01 %
10,47 %
29,42 %
1 Jan 2026 (e)
52,01 %
-15,80 %
10,40 %
1 Jan 2027 (e)
52,01 %
-15,94 %
10,74 %
1 Jan 2028 (e)
52,01 %
-15,78 %
11,40 %

Pendapatan Saham Bio Rad Laboratories, EBIT, Laba Per Saham

Pendapatan per saham Bio Rad Laboratories dengan demikian menunjukkan berapa banyak pendapatan yang telah dihasilkan Bio Rad Laboratories per saham dalam periode tertentu. Laba sebelum bunga dan pajak per saham menunjukkan berapa banyak laba operasional yang sesuai dengan setiap saham. Laba per saham menunjukkan berapa banyak laba yang dimiliki setiap saham.

  • 3 tahun

  • 5 tahun

  • 10 tahun

  • 25 Tahun

  • Maks

Pendapatan per Saham
EBIT per saham
Laba Per Saham
Details
Date
Pendapatan per Saham
EBIT per saham
Laba Per Saham
1 Jan 2021
97,67 USD
16,77 USD
142,18 USD
1 Jan 2022
94,06 USD
16,20 USD
-121,76 USD
1 Jan 2023
92,70 USD
11,72 USD
-22,12 USD
1 Jan 2024
91,67 USD
9,61 USD
-65,87 USD
1 Jan 2025
95,63 USD
10,01 USD
28,13 USD
1 Jan 2026 (e)
91,21 USD
-15,05 USD
9,48 USD
1 Jan 2027 (e)
93,34 USD
-15,54 USD
10,03 USD
1 Jan 2028 (e)
97,78 USD
-16,12 USD
11,15 USD

Model bisnis dan analisis saham Bio Rad Laboratories

Bio-Rad Laboratories Inc. is a leading company in the field of scientific research based in Hercules, California. The company was founded in 1952 by two brothers and has since developed into a multinational company with over 8,000 employees worldwide. Bio-Rad has branches in over 100 countries and its products are used in biotechnology, pharmaceuticals, and the food industry. History Bio-Rad was founded in 1952 by the couple David and Alice Schwartz. They started with the production of blood group serology tests and later expanded their product range to include immunchemicals, electrophoresis equipment, and antibodies. In the 1970s, Bio-Rad developed the first commercial protein A purification system, which is still an important component of protein research today. Business model Bio-Rad's business model is focused on providing high-quality products and services to support customers in their scientific research. The company has various divisions such as life science research, clinical diagnostics, and life science education, which offer products and solutions for scientists, researchers, and diagnosticians. Life science research The life science research division offers a wide range of products and services for biological research. This includes PCR systems, electrophoresis equipment, antibodies, proteins, cell counters, and much more. Bio-Rad's products are used by scientists and researchers around the world to better understand the intricacies of life and the mechanisms of diseases. Clinical diagnostics Bio-Rad's clinical diagnostics division provides a broad spectrum of diagnostic products and solutions for hospitals, laboratories, and medical facilities. The company provides clinical diagnostic instruments, reagents, testing systems, and software to support the diagnostic process. Life science education The life science education division offers innovative and interactive teaching and learning materials for scientific research to teachers, professors, and students. Bio-Rad's products and solutions support the better understanding of the intricacies of life and the mechanisms of diseases in the fields of biology, chemistry, and physics. Products Bio-Rad offers a wide range of products and solutions for research and diagnostics. These include, among others: PCR systems: Bio-Rad offers various PCR systems that help researchers and diagnosticians amplify and analyze DNA. The systems are highly precise and provide reliable results. Proteins and antibodies: Bio-Rad offers a wide selection of proteins and antibodies for research and diagnostics. The products include various types of proteins and antibodies needed for the analysis of protein functions and interactions. Electrophoresis equipment: Bio-Rad provides various electrophoresis equipment that plays an important role in research and diagnostics. The products include gel electrophoresis systems, Western blot systems, and devices for protein analysis. Clinical diagnostics: Bio-Rad offers a wide range of diagnostic products for hospitals, laboratories, and medical facilities. These include immunoassay products, blood group serology tests, and devices for the diagnosis of infectious diseases. In summary, Bio-Rad Laboratories Inc. is a leading company in the field of scientific research. The company offers a wide range of products and solutions for research and diagnostics, supporting scientists, researchers, and diagnosticians around the world in exploring the intricacies of life and better understanding diseases.

Bio Rad Laboratories Employees

  • 3 tahun

  • 5 tahun

  • 10 tahun

  • 25 Tahun

  • Maks

Bio Rad Laboratories Employees
Details
Date
Bio Rad Laboratories Employees
1 Jan 2018
- Employees
1 Jan 2019
- Employees
1 Jan 2020
- Employees
1 Jan 2021
- Employees
1 Jan 2022
- Employees
1 Jan 2023
- Employees
1 Jan 2024
- Employees
1 Jan 2025
- Employees

Bio Rad Laboratories Segmen

Pendapatan Bio Rad Laboratories menurut Segmen (1/3)

  • 3 tahun

  • 5 tahun

  • Maks

Clinical Diagnostics
Life Science
Details
Date
Clinical Diagnostics
Life Science
1 Jan 2019
1,41 miliar USD
0,00 USD
1 Jan 2020
1,31 miliar USD
1,23 miliar USD
1 Jan 2021
1,52 miliar USD
1,40 miliar USD
1 Jan 2022
1,45 miliar USD
1,35 miliar USD
1 Jan 2023
1,49 miliar USD
1,18 miliar USD

Pendapatan Bio Rad Laboratories menurut Segmen (2/3)

  • 3 tahun

  • 5 tahun

  • Maks

All Other Segments
Details
Date
All Other Segments
1 Jan 2019
0,00 USD
1 Jan 2020
8,60 Juta. USD
1 Jan 2021
5,80 Juta. USD
1 Jan 2022
4,00 Juta. USD
1 Jan 2023
3,60 Juta. USD

Pendapatan Bio Rad Laboratories menurut Segmen (3/3)

  • 3 tahun

  • 5 tahun

  • Maks

Life Science
All Other Segments
Details
Date
Life Science
All Other Segments
1 Jan 2019
885,90 Juta. USD
13,80 Juta. USD
1 Jan 2020
0,00 USD
0,00 USD
1 Jan 2021
0,00 USD
0,00 USD
1 Jan 2022
0,00 USD
0,00 USD
1 Jan 2023
0,00 USD
0,00 USD

Pendapatan Bio Rad Laboratories menurut Wilayah

  • 3 tahun

  • 5 tahun

  • Maks

United States
Europe
Asia
Other (primarily Canada and Latin America)
Details
Date
United States
Europe
Asia
Other (primarily Canada and Latin America)
1 Jan 2019
899,10 Juta. USD
770,30 Juta. USD
505,00 Juta. USD
137,30 Juta. USD
1 Jan 2020
1,00 miliar USD
857,70 Juta. USD
546,50 Juta. USD
136,60 Juta. USD
1 Jan 2021
1,13 miliar USD
946,90 Juta. USD
688,40 Juta. USD
156,60 Juta. USD
1 Jan 2022
1,16 miliar USD
851,90 Juta. USD
639,40 Juta. USD
155,40 Juta. USD
1 Jan 2023
1,12 miliar USD
819,80 Juta. USD
563,00 Juta. USD
166,60 Juta. USD
1 Jan 2024
1,04 miliar USD
834,10 Juta. USD
521,60 Juta. USD
169,30 Juta. USD
1 Jan 2025
1,02 miliar USD
881,80 Juta. USD
513,30 Juta. USD
165,40 Juta. USD

Penilaian Bio Rad Laboratories berdasarkan Fair Value

Detail

Estimasi Nilai Wajar

ⓘ

Apa Itu Nilai Wajar?

Nilai wajar adalah estimasi dari apa yang benar-benar "bernilai" dari saham berdasarkan fundamental keuangannya, terlepas dari harga pasar saat ini. Jika nilai wajar yang dihitung berada di atas harga saham saat ini, saham mungkin dinilai terlalu rendah — dan sebaliknya. Grafik ini menunjukkan tiga pendekatan nilai wajar yang berbeda sehingga Anda dapat saling memeriksa mereka.

Nilai Wajar Berbasis Laba

Dihitung dengan mengalikan laba per saham (EPS) saat ini dengan rata-rata rasio P/E historis selama periode multi-tahun yang dipilih. Perataan selama beberapa tahun menyaring lonjakan atau penurunan sementara. Jika nilai wajar ini melebihi harga pasar, ini menunjukkan bahwa saham murah relatif terhadap kekuatan penghasilannya.

Contoh: Nilai Wajar (Laba) 2022 = EPS 2022 × Rata-rata P/E 2019–2021

Nilai Wajar Berbasis Pendapatan

Diturunkan dengan mengalikan pendapatan per saham dengan rata-rata rasio harga-ke-penjualan historis. Metode ini sangat berguna untuk perusahaan dengan laba yang volatil atau sementara tertekan, karena pendapatan cenderung lebih stabil daripada laba. Ini menjawab: "Pada harga berapa pasar secara historis menilai setiap dolar penjualan perusahaan ini?"

Contoh: Nilai Wajar (Pendapatan) 2022 = Pendapatan per Saham 2022 × Rata-rata P/S 2019–2021

Nilai Wajar Berbasis Dividen

Dihitung dengan membagi dividen per saham dengan rata-rata hasil dividen historis. Pendekatan ini paling relevan untuk perusahaan matang yang secara konsisten membayar dividen. Jika nilai wajar yang dihasilkan lebih tinggi dari harga saat ini, ini menyiratkan bahwa saham menawarkan hasil yang lebih baik daripada rata-rata historisnya.

Contoh: Nilai Wajar (Dividen) 2022 = Dividen per Saham 2022 ÷ Rata-rata Hasil 2019–2021

Cara Menggunakan Grafik Ini

Ketika ketiga garis nilai wajar bertemu di atas harga saat ini, ini memperkuat kasus bahwa saham dinilai terlalu rendah. Ketika mereka divergen, selidiki mengapa — ini mungkin menunjukkan perubahan struktural dalam margin, kebijakan pembayaran, atau tingkat pertumbuhan. Estimasi maju di sisi kanan memperluas analisis menggunakan fundamental yang diproyeksikan, membantu Anda menilai apakah harga saat ini sudah mencerminkan harapan pertumbuhan masa depan.

Penilaian Bio Rad Laboratories berdasarkan PER historis, EBIT multiple, dan PSR

Pengembalian tahunan Bio Rad Laboratories

Detail

Pengembalian Tahunan

ⓘ

Apa yang Grafik Ini Tunjukkan

Grafik ini memecah pengembalian tahunan total menjadi dua komponen: pengembalian harga (keuntungan atau kerugian dari pergerakan harga saham) dan pengembalian dividen (pendapatan yang diterima dari pembayaran dividen). Bersama-sama, mereka mewakili total pengembalian yang akan diperoleh investor di setiap tahun kalender.

Pengembalian Harga

Pengembalian harga mengukur perubahan persentase dalam harga saham dari 1 Januari hingga 31 Desember setiap tahun. Batang positif menunjukkan saham dihargai; batang negatif menunjukkan penurunan. Ini adalah komponen yang paling difokuskan oleh investor, tetapi itu hanya menceritakan sebagian dari cerita — terutama untuk saham pembayar dividen.

Pengembalian Dividen

Pengembalian dividen mewakili pendapatan yang dihasilkan dari dividen yang dibayarkan selama tahun tersebut, dinyatakan sebagai persentase dari harga saham awal. Meskipun mungkin tampak kecil dalam satu tahun apa pun (biasanya 1–4% untuk perusahaan yang sudah mapan), dividen menggabungkan secara signifikan selama beberapa dekade dan secara historis telah berkontribusi sekitar 40% dari total pengembalian pasar saham.

Apa yang Perlu Dicari

Periksa berapa banyak tahun yang menunjukkan pengembalian positif vs. negatif untuk mengukur konsistensi. Saham dengan sebagian besar tahun positif dan drawdown kecil menunjukkan risiko yang lebih rendah. Juga bandingkan pengembalian tahunan dengan indeks benchmark — secara konsisten melampaui pasar adalah ciri investasi yang kuat. Perhatikan tahun-tahun terburuk: memahami risiko penurunan sama pentingnya dengan mengejar potensi naik.

Saham beredar Bio Rad Laboratories

Jumlah saham Bio Rad Laboratories pada tahun 2025 adalah 27,01 Juta.. Ini menunjukkan menjadi berapa banyak saham Bio Rad Laboratories dibagi. Karena pemegang saham adalah pemilik perusahaan, setiap saham mewakili sebagian kecil dari kepemilikan perusahaan.

  • 3 tahun

  • 5 tahun

  • 10 tahun

  • 25 Tahun

  • Maks

Jumlah saham
Details
Date
Jumlah saham
1 Jan 2021
29,92 Juta. Saham
1 Jan 2022
29,79 Juta. Saham
1 Jan 2023
28,82 Juta. Saham
1 Jan 2024
28,00 Juta. Saham
1 Jan 2025
27,01 Juta. Saham
1 Jan 2026 (e)
27,01 Juta. Saham
1 Jan 2027 (e)
27,01 Juta. Saham
1 Jan 2028 (e)
27,01 Juta. Saham

Prakiraan Bio Rad Laboratories dan target harga saat ini di Agustus 2026

Target Harga Analis 2026
Δ Target harga dari bulan sebelumnya
0,00 %
Beli
60,00 % (6)
Tahan
40,00 % (4)
Jual
0,00 % (0)
Target Harga 12 Bulan
372,30
Harga terakhir
356,26
Mata uang
USD
Potensi Pengembalian 12M
4,50 %
Hasil LTM
0 %

Bio Rad Laboratories Analyst Rating Actions

DateFirmActionRatingReliability
1/5/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
7/4/2026
Citigroup
Citigroup
DowngradeBuyNeutral48
16/2/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
30/10/2025
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
30/10/2025
Citigroup
Citigroup
MaintainedBuy48
1/8/2025
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
1/8/2025
RBC Capital
RBC Capital
MaintainedOutperform52
9/6/2025
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
2/5/2025
UBS
UBS
MaintainedBuy51
2/5/2025
RBC Capital
RBC Capital
MaintainedOutperform52

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Bio Rad Laboratories Estimasi dan Kejutan Laba

TanggalPerkiraan EPSEPS AktualPerkiraan PendapatanReaksi hargaKuartal Laporan
30/7/20261,77USD-630,23 Juta.USD-2026 Q2
30/4/20262,00USD-594,76 Juta.USD-2026 Q1
12/2/20262,74USD-700,89 Juta.USD-2025 Q4
2/5/20243,35USD-673,76 Juta.USD-2024 Q1
14/2/20242,89USD-692,41 Juta.USD-2023 Q4
28/7/20222,83USD-692,86 Juta.USD-2022 Q2
7/8/20181,28USD-556,66 Juta.USD-2018 Q2

EESG©

Rating Eulerpool ESG untuk saham Bio Rad Laboratories

41/100
41
Environment
62
Social
20
Governance
E

Lingkungan (Environment)

20
Emisi Langsung.10.563
Emisi tidak langsung dari energi yang dibeli.13.906
Emisi tidak langsung dalam rantai nilai295.930
Emisi CO₂24.469
Strategi Reduksi CO₂
Energi Batubara
Energi Nuklir
Percobaan pada hewan
Bulu & Kulit—
Pestisida—
Minyak Sawit—
Tembakau
Bioteknologi
Konsep Iklim—
Pengelolaan Hutan Berkelanjutan—
Peraturan Daur Ulang
Kemasan Ramah Lingkungan
Bahan berbahaya
Konsumsi dan Efisiensi Bahan Bakar
Penggunaan dan Efisiensi Air
S

Sosial (Social)

20
Persentase Karyawan Wanita44
Proporsi Wanita dalam Manajemen—
Porsi Karyawan Asia—
Porsi Manajemen Asia—
Proporsi Karyawan Hispanik/Latino—
Porsi Manajemen Hispanik/Latino—
Porsi Karyawan Berkulit Hitam—
Porsi Manajemen Hitam—
Proporsi Karyawan Kulit Putih—
Porsi manajemen berkulit putih—
Konten Dewasa
Alkohol
Pertahanan—
Senjata api
Judi
Kontrak Militer
Konsep Hak Asasi Manusia
Konsep Perlindungan Data—
Kesehatan dan Keselamatan Kerja
Katolik
G

Tata Kelola Perusahaan (Governance)

4
Laporan Keberlanjutan
Stakeholder-Engagement
Kebijakan Pemanggilan Kembali
Hukum Anti Monopoli

Rating Eulerpool ESG yang terkenal adalah milik intelektual yang dilindungi hak cipta secara ketat oleh Eulerpool Research Systems. Setiap penggunaan tanpa izin, peniruan, atau pelanggaran akan dikejar secara tegas dan dapat berakibat pada konsekuensi hukum yang signifikan. Untuk lisensi, kerja sama, atau hak penggunaan, silakan hubungi kami langsung melalui. Formulir Kontak kepada kami.

Struktur pemegang saham Bio Rad Laboratories

% Nama
9,22511%
FIRST EAGLE INVESTMENT MANAGEMENT, LLC
FIRST EAGLE INVESTMENT MANAGEMENT, LLC
5,95470%
BLACKROCK, INC.
BLACKROCK, INC.
3,86093%
DIMENSIONAL FUND ADVISORS LP
DIMENSIONAL FUND ADVISORS LP
2,94593%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
2,93892%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
2,78571%
ARIEL INVESTMENTS, LLC
ARIEL INVESTMENTS, LLC
...

Bio Rad Laboratories Beneficial Ownership Filings (SEC 13D/G)

Free Float
66,1%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
87,40%
Schwartz
Schwartz
SEC ↗
83,70%
943334150
943334150
SEC ↗
80,80%
Steven D. Schwartz
Steven D. Schwartz
SEC ↗
80,10%
Blue Raven Partners, L.P.
Blue Raven Partners, L.P.
SEC ↗
79,20%
Blue Raven Partners, L.P., 943334150
Blue Raven Partners, L.P., 943334150
SEC ↗
14,60%
Norman D. Schwartz
Norman D. Schwartz
SEC ↗
12,30%
Alice N. Schwartz
Alice N. Schwartz
SEC ↗
11,40%
First Eagle Investment Management, LLC
First Eagle Investment Management, LLC
SEC ↗
11,00%
Eaton Vance Management 04-3101341
Eaton Vance Management 04-3101341
SEC ↗
9,70%
BIO-RAD LABORATORIES, INC
BIO-RAD LABORATORIES, INC
SEC ↗

Bio Rad Laboratories Dewan Direksi dan Dewan Komisaris

16 members · avg. age 60 · 31 % women

NS

Mr. Norman Schwartz (75)

Chairman of the Board, Chief Executive Officer · sejak 1995

8,29 Juta. USD

Management

JD

Mr. Jonathan Divincenzo (59)

President, Chief Operating Officer

4,31 Juta. USD
RL

Mr. Roop Lakkaraju (54)

Chief Financial Officer, Executive Vice President

3,78 Juta. USD
MC

Mr. Michael Crowley (63)

Executive Vice President - Global Commercial Operations

2,24 Juta. USD
EE

Ms. Eva Anette Engelhardt (55)

Executive Vice President, President of Clinical Diagnostics Group

2,23 Juta. USD
CE

Ms. Courtney Enloe (53)

Executive Vice President, General Counsel, Secretary

–
CC

Ms. Colleen Corey (63)

Executive Vice President, Global Human Resources

–

Board of Directors

GH

Mr. Gregory Hinckley (78)

Lead Independent Director

339.563,00 USD
ML

Ms. Melinda Litherland (67)

Independent Director

331.563,00 USD
JE

Mr. Jeffrey Edwards (64)

Independent Director

326.563,00 USD
AP

Mr. Arnold Pinkston (66)

Independent Director

311.563,00 USD
AS

Ms. Allison Schwartz (44)

Director

–

Bio Rad Laboratories Supply Chain

Bio Rad Laboratories Rantai pasokan

Korelasi: seberapa erat harga saham bergerak bersama

Arah yang samaTidak ada hubunganBerlawanan
14 companies
#Namaβ 1YTrend
1
Sartorius Vz
Pemasok·Pelanggan·DE
0,39
0,51
0,86
0,96
0,96
0,94
—
2
Danaher Corporation
Pelanggan·Life Sciences Tools & Services·US
0,89
0,85
0,92
0,92
0,90
0,87
0,89
3
Biotest Vz I
Pemasok·DE
-0,17
0,14
-0,26
0,83
0,40
0,68
—
#Namaβ 1YTrend
1
Quantum-Si A
Pemasok·Pelanggan·Life Sciences Tools & Services·US
0,97
0,58
0,61
0,84
0,64
—
—
2
Seegene, Inc.
Pelanggan·Biotechnology·KR
0,78
0,54
0,58
0,82
0,54
—
0,92
3
Luminex Corporation
Pemasok·US
0,58
0,46
-0,25
-0,89
-0,90
—
-4,05
4
DCC plc
Pelanggan
-0,09
-0,43
—
—
—
—
—
5
Biodesix
Pemasok·Pelanggan·Health Care Providers & Services·US
-0,47
-0,25
0,36
0,85
0,59
—
—

Pertanyaan yang sering diajukan tentang saham Bio Rad Laboratories

The business model of Bio Rad Laboratories Inc. revolves around refining and providing innovative solutions for the life science research and diagnostic markets. As a leading global provider of products and systems, Bio Rad Laboratories Inc. focuses on developing and manufacturing a wide range of specialized products. These include instruments, reagents, consumables, software, and services that cater to medical diagnostics, scientific research, and biopharmaceutical production. By continuously investing in research and development, Bio Rad Laboratories Inc. aims to meet the diverse needs of its customers, drive scientific advancements, and improve patient outcomes worldwide.

Bio Rad Laboratories Inc operates primarily in the Life Sciences and Clinical Diagnostics industries. As a leading global provider of specialty diagnostic solutions, Bio Rad offers a wide range of products and services for scientific research and healthcare diagnostics. The company specializes in developing and manufacturing instruments, reagents, software, and consumables for applications in life science research, clinical laboratories, and pharmaceutical production. With a focus on advancing scientific discovery and improving patient healthcare, Bio Rad Laboratories Inc plays a crucial role in the fields of molecular biology, genomics, proteomics, and more.

Some of the main competitors of Bio Rad Laboratories Inc in the market include Thermo Fisher Scientific Inc, PerkinElmer Inc, and Illumina Inc.

Bio Rad Laboratories Inc, established in 1952, is a global leader in life science research and clinical diagnostics. The company's rich history spans over several decades, during which it has consistently provided innovative solutions to scientists and healthcare professionals. Bio Rad initially focused on the development of specialized products for the growing field of biochemical research, and later expanded into medical diagnostics and life science technologies. Today, Bio Rad continues to deliver cutting-edge technology, spanning areas such as genomics, proteomics, cell biology, food safety, and more. With a commitment to excellence and advancements in healthcare, Bio Rad Laboratories Inc remains a trusted name in the scientific community.

Bio Rad Laboratories Inc has accomplished several significant milestones. From its inception in 1952, the company has become a global leader in life science research and clinical diagnostics. One noteworthy achievement is the development of ground-breaking products, such as the first digital imaging system for electrophoresis analysis, which revolutionized the field. Bio Rad also played a crucial role in advancing HIV/AIDS diagnostics and monitoring through the introduction of reliable testing systems. Additionally, the company's continuous dedication to innovation has led to expansions in various areas, including food safety and quality control, further strengthening its position as a trusted provider of scientific solutions across industries. Bio Rad Laboratories Inc remains committed to driving advancements and enhancing scientific research globally.

Bio Rad Laboratories Inc is primarily present in the United States, with its headquarters located in Hercules, California. Aside from its domestic presence, Bio Rad operates internationally in various countries and regions. This includes Europe (with offices in the United Kingdom, France, Germany, and other countries), Asia-Pacific (including Japan, China, Korea, and Australia), Latin America, and Canada. With its extensive global footprint, Bio Rad Laboratories Inc continues to expand its reach and serve customers worldwide in the life sciences and clinical diagnostics industries.

Bio Rad Laboratories Inc represents a strong set of values and a dedicated corporate philosophy. The company is committed to providing innovative solutions and high-quality products in the life sciences and clinical diagnostics fields. Bio Rad prioritizes excellence, integrity, and teamwork in all its endeavors. With a focus on customer satisfaction, Bio Rad strives to deliver superior value and support to its clients. The company's relentless dedication to scientific advancement and commitment to ethical and responsible business practices contribute to its reputable standing in the industry.

Analysts currently set an average price target of 362,10 USD for the Bio Rad Laboratories stock (median: 372,30 USD), implying +1,6 % versus the latest price. The consensus is based on 10 analyst ratings.

Bio Rad Laboratories Target Harga Analis 2026

10 analysts currently rate the Bio Rad Laboratories stock: 6 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Bio Rad Laboratories to generate revenue of 2,57 miliar USD and earnings per share of 9,91 USD.

Bio Rad Laboratories Target Harga Analis 2026

Converted at the current exchange rate, the Bio Rad Laboratories share trades at 307,50 EUR (356,26 USD).

The Bio Rad Laboratories share (BIO) is listed on 6 stock exchanges, including: NYSE (BIO), XETRA (BUWA.DE), Frankfurt (BUWA.F), München (BUWA.MU), Düsseldorf (BUWA.DU), SIX (Zürich) (BUWA.SW).

Bio Rad Laboratories Inc is a globally operating company in the field of life science research, diagnostics, and biopharmaceuticals. The company offers a wide range of innovative products and services for research institutions, biotechnology and pharmaceutical companies, as well as customers in clinical diagnostics. The business strategy of Bio Rad Laboratories is based on three pillars: product innovation, diversification, and global expansion. The company continuously invests in research and development to develop new products and services that meet the needs of its customers. Thanks to the diversification of its product lines, Bio Rad Laboratories is able to expand in various areas of life sciences and address a wide spectrum of customers. The company is divided into six main business areas: 1. Life Science Research Bio Rad Laboratories offers a comprehensive range of life science research products for research in genomics, proteomics, cell biology, and immunology. Products include DNA isolation kits, PCR reagents, protein separation systems, and antibody solutions. 2. Diagnostics Bio Rad Laboratories is a leading provider of in vitro diagnostics and QC/QA products. The company offers diagnostic products for clinical chemistry, hematology, immunology, and microbiology. 3. Biopharma Bio Rad Laboratories offers a wide range of solutions for biopharmaceuticals, including chromatography columns, protein purification systems, and analysis equipment. 4. Food Science Bio Rad Laboratories offers products for food quality assurance. This includes products for the identification of contaminants in food, such as salmonella, E. coli, and other bacterial contaminations, as well as for testing the nutrient quality in food. 5. Process Separations Bio Rad Laboratories offers a comprehensive range of chromatography columns and accessories used for downstream purification of proteins and other biomolecules in biopharmaceuticals and the food industry. 6. Digital Biology Bio Rad Laboratories offers solutions for digital PCR analysis with its droplet digital PCR technology. This technology allows for the quantification of nucleic acids on an absolute basis and can be used in numerous applications in research and diagnostics. The company also offers software solutions that simplify and standardize data recording and analysis in laboratory tests. The offered software solutions include laboratory information management systems (LIMS), chromatography software, and data analysis tools. Bio Rad Laboratories' customers include research institutions, biotechnology and pharmaceutical companies, as well as customers in clinical diagnostics. The company's products and services are sold in over 100 countries worldwide. In conclusion, Bio Rad Laboratories offers a wide portfolio of products and services in the field of life science research, diagnostics, and biopharmaceuticals. The company pursues a business strategy based on product innovation, diversification, and global expansion. Thanks to the wide range of products and services designed for different business areas, Bio Rad Laboratories is able to serve a broad spectrum of customers worldwide.

Pendapatan diperkirakan dari Bio Rad Laboratories adalah 2,57 miliar USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.

Laba diperkirakan dari Bio Rad Laboratories adalah 267,56 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.

Rasio harga-terhadap-pendapatan (PER) Bio Rad Laboratories saat ini adalah 35,97. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Bio Rad Laboratories.

Rasio harga-terhadap-penjualan (PSR) Bio Rad Laboratories saat ini adalah 3,74. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Bio Rad Laboratories.

Skor Kualitas AlleAktien untuk Bio Rad Laboratories adalah 2/10.

ISIN dari Bio Rad Laboratories adalah US0905722072. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.

WKN dari Bio Rad Laboratories adalah 865406. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.

Ticker dari Bio Rad Laboratories adalah BIO. Simbol ticker digunakan untuk memperdagangkan saham Bio Rad Laboratories di bursa saham.

Bio Rad Laboratories membayar dividen setiap tahun dalam 0 tahun terakhir.

Bio Rad Laboratories dikelompokkan dalam sektor 'Kesehatan'.

Dividen dari Bio Rad Laboratories dibayarkan dalam USD.

Semua metrik fundamental dan analisis mendalam Bio Rad Laboratories

Analisis saham kami untuk saham Bio Rad Laboratories mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Bio Rad Laboratories. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.

Bio Rad Laboratories Saham
Bio Rad Laboratories Pendapatan→
Bio Rad Laboratories Saham
Bio Rad Laboratories Keuntungan→
Bio Rad Laboratories Saham
Bio Rad Laboratories PER→
Bio Rad Laboratories Saham
Bio Rad Laboratories P/S→
Bio Rad Laboratories Saham
Bio Rad Laboratories EBIT→
Bio Rad Laboratories Saham
Bio Rad Laboratories Dividen→
Bio Rad Laboratories Saham
Bio Rad Laboratories Pembelian Insider→
Bio Rad Laboratories Saham
Bio Rad Laboratories Saham→
Bio Rad Laboratories Saham
Bio Rad Laboratories Kapitalisasi Pasar→
Bio Rad Laboratories Saham
Bio Rad Laboratories Utang→
Bio Rad Laboratories Saham
Bio Rad Laboratories Utang→
Bio Rad Laboratories Saham
Bio Rad Laboratories Modal sendiri→
Bio Rad Laboratories Saham
Bio Rad Laboratories AAQS→
Bio Rad Laboratories Saham
Bio Rad Laboratories Karyawan→
Bio Rad Laboratories Saham
Bio Rad Laboratories ROE→
Bio Rad Laboratories Saham
Bio Rad Laboratories ROA→
Bio Rad Laboratories Saham
Bio Rad Laboratories ROCE→
Bio Rad Laboratories Saham
Bio Rad Laboratories News→
Bio Rad Laboratories Saham
Bio Rad Laboratories Target Harga Analis→

Kesehatan Saham

Bio Solution CoBio Preventive MedicineBio ViewBio Plus CoBio-FD&C CoBio Path HoldingsBio-TechneBio Green Med SolutionBio-Thera SolutionsBinex CoBio-Works TechnologiesBimergen EnergySemua Saham A–Z →